Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.0698
Abstract: Key Points Question Can the outcomes of pivotal trials conducted among patients with extensive-stage small cell lung cancer (ES-SCLC) be applied in a clinical practice setting? Findings In this cohort study of 207 patients with… read more here.
Keywords: eligibility; trial; stage small; patients extensive ... See more keywords
Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5738
Abstract: Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and supportive care use among patients with… read more here.
Keywords: oncology; myelosuppression; patients extensive; extensive stage ... See more keywords
Durvalumab: A Review in Extensive-Stage SCLC
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-021-00843-0
Abstract: Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small… read more here.
Keywords: chemotherapy; combination; durvalumab; extensive stage ... See more keywords
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.02.026
Abstract: OBJECTIVES Despite intensive research, the therapeutic options in extensive-stage small cell lung cancer (SCLC) are still limited. Data from routine clinical practice, so-called "real-world data", are centrally important to assess and improve the standard of… read more here.
Keywords: second third; third line; line; treatment ... See more keywords
Adebrelimab versus serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis in China.
Sign Up to like & getrecommendations! Published in 2024 at "International journal of technology assessment in health care"
DOI: 10.1017/s0266462324000175
Abstract: Objective : We aimed to evaluate the cost-effectiveness of two first-line treatments newly approved 11 in the Chinese market for the treatment of extensive-stage small-cell lung cancer (ES-SCLC), 12 namely, adebrelimab plus chemotherapy (carboplatin+etoposide) and… read more here.
Keywords: plus chemotherapy; first line; treatment extensive; stage small ... See more keywords
Machine learning-based prediction model for brain metastasis in patients with extensive-stage small cell lung cancer
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-80425-y
Abstract: Brain metastases (BMs) in extensive-stage small cell lung cancer (ES-SCLC) are often associated with poor survival rates and quality of life, making the timely identification of high-risk patients for BMs in ES-SCLC crucial. Patients diagnosed… read more here.
Keywords: brain; stage; model; extensive stage ... See more keywords
Comparison of efficacy and safety of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer, a retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-23874-3
Abstract: Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis, in combination with platinum-based chemotherapy, have become the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). Among these agents, serplulimab is a PD-1 inhibitor, while adebrelimab,… read more here.
Keywords: lung cancer; cell lung; small cell; extensive stage ... See more keywords
Navigating first-line therapies for extensive-stage small-cell lung cancer: a frequentist network meta-analysis and systematic review.
Sign Up to like & getrecommendations! Published in 2024 at "Future oncology"
DOI: 10.1080/14796694.2024.2376514
Abstract: Aim: To identify the optimal first-line treatment for patients with extensive-stage small-cell lung cancer (ES-SCLC). Materials & methods: We conducted a network meta-analysis (CRD42023486863) to systematically evaluate the efficacy and safety of eight first-line treatment… read more here.
Keywords: analysis; small cell; first line; extensive stage ... See more keywords
The value and safety of trilaciclib in combination with first-line chemotherapy and immunotherapy for extensive-stage SCLC.
Sign Up to like & getrecommendations! Published in 2025 at "Immunotherapy"
DOI: 10.1080/1750743x.2025.2559578
Abstract: AIMS To evaluate the myeloprotective effects, safety, and survival outcomes of trilaciclib in first-line chemotherapy for extensive-stage small cell lung cancer (ES-SCLC) in China. METHODS A single-center, retrospective study was conducted with 120 ES-SCLC patients… read more here.
Keywords: immunotherapy; first line; line chemotherapy; extensive stage ... See more keywords
Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?
Sign Up to like & getrecommendations! Published in 2025 at "Medicine"
DOI: 10.1097/md.0000000000044383
Abstract: Background: This study addresses the lack of a comprehensive meta-analysis comparing the efficacy and safety of first-line anti-blocking the programmed cell death 1 (PD-1) and anti-programmed death ligand 1 (PD-L1) therapies in patients with extensive-stage… read more here.
Keywords: anti; first line; anti inhibitors; cell ... See more keywords
Impact of thoracic radiation therapy after chemotherapy on survival in extensive‐stage small cell lung cancer: A propensity score‐matched analysis
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13001
Abstract: The role of thoracic radiation therapy (TRT) after chemotherapy (CHT) in extensive‐stage small cell lung cancer (ES‐SCLC) has not been well defined. We investigated whether intensity‐modulated radiotherapy (IMRT) improves outcomes in ES‐SCLC after CHT compared… read more here.
Keywords: radiation therapy; stage small; thoracic radiation; extensive stage ... See more keywords